Educational resources are an essential component of the mission of PCSK9 Forum to increase awareness and understanding of PCSK9 science and therapeutics.

Complementing resources already available, PCSK9 Forum is pleased to announce the next in this series of educational slide decks which specifically focus on defining patient groups likely to benefit more from PCSK9 inhibition. These decks provide the essentials from these analyses of PCSK9 inhibitor trials, together with expert interpretation from the PCSK9 Forum Editorial Board. They offer accessible education for clinicians involved in the management of very high-risk patients in their routine practice.

FOURIER subgroup analysis: severity and extent of coronary artery disease Patients with recent or multiple MIs and/or multivessel coronary artery disease are likely to benefit more from PCSK9 inhibition.

ODYSSEY-DM Insulin The first randomised trial data in patients with type 1 or 2 diabetes mellitus on insulin therapy.

Bookmark PCSK9 Forum to return for regular updates to this innovative expert-led educational slide resource programme.